Status:
COMPLETED
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
Lead Sponsor:
Summa Health System
Conditions:
Glaucoma
Application Site Pigmentation Changes
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.
Detailed Description
One uncommon side effect of prostaglandin eye drops is a change in color of the skin around the eyes, which is reversible. There are three different brands of the medicine which are equally effective ...
Eligibility Criteria
Inclusion
- patients recently diagnosed with primary open angle glaucoma or ocular hypertension
- Caucasian and African American ethnicities
- Male and Female
- Age 30 and above
Exclusion
- A history of ocular medication use within the last 12 months
- Inflammatory/ allergic skin diseases or dermatitis
- presence of periocular hyperpigmented skin lesions
- Systemic pigmentation disorders
- Use of systemic drugs that can affect skin pigmentation
- Visitation of tanning salons, or use of self tanning products
- Pregnancy or patients planning to become pregnant in the near future
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT00705757
Start Date
March 1 2008
End Date
April 1 2011
Last Update
January 18 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Arlington Eye Physicians
Arlington Heights, Illinois, United States, 60005
2
Summa Health System
Akron, Ohio, United States, 44304